The volume of the target segment of the Russian pharmaceutical market in the 1^st half of 2017 reached a value of 30 billion rubles, and the volume of 0.07 billion packages. 

Based on the results of the first half of 2017, medicinal products deliveries were made under the High-cost diseases (HCD) program for the amount of almost 25 billion rubles. This is more than a half of the amount budgeted for this item of expenditure for the year. It is assumed that by the end of 2017, the costs of procurement for HCD will exceed 2016’s costs, and will reach the level of previous years